Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ACYCLOVIR

All products: general benefit

Other products in the same Health Canada class (J05A, J05AB) — coverage varies; not interchangeable

  • Ganciclovir (Cytovene): general benefit
  • Valacyclovir (Valtrex): general benefit, Not a benefit
  • Famciclovir (Famvir): limited Use 147, Not a benefit
  • Remdesivir (Veklury): limited Use 722
  • Valganciclovir (Valcyte): limited Use 374, 568, 569, Limited Use 571, 572, 573
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

48 more in the class list below

Mylan-Acyclovir · DIN 02242784 · 200mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Acyclovir · DIN 02242784 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2001-06-07 Health Canada: Marketed since 2010-02-12 · brand MYLAN-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Acyclovir: Formulary list price $0.3511/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3511 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66607 · Verify on the e-Formulary ↗ (DIN 02242784)

Source record
DIN 02242784: Mylan-Acyclovir Raw flags: sec3=Y Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id MYL Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.3511; ministry $0.3511 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242784 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66607
Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511 Mint-Acyclovir · DIN 02524708 · $0.3511 Teva-Acyclovir · DIN 02285959 · $0.3511 Zovirax · DIN 00634506 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

GANCICLOVIR SODIUM

· 1 products · General benefit · strengths: 500mg/Vial · Pd Inj-10mL Pk

VALACYCLOVIR

· 21 products · General benefit (13), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 500mg, 1000mg · Tab

FAMCICLOVIR

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (4), Limited Use, codes 147 (2) · strengths: 125mg, 250mg, 500mg · Tab

REMDESIVIR

· 1 products · Limited Use, codes 722 · strengths: 100mg/vial · Pd for Sol-100mg Vial Pk

VALGANCICLOVIR

· 6 products · Limited Use, codes 571, 572, 573 (2), Limited Use, codes 374, 568, 569 (4) · strengths: 50mg/mL, 450mg · Pd for Oral Sol-100mL Pk, Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Zovirax (acyclovir 5%) cream is indicated for the topical management of initial episodes of genital herpes simplex infections. The prophylactic use of this preparation has not been established. Zovirax (acyclovir 5%) ointment is for the management of initial episodes of genital herpes simplex infections. It is also indicated in the management of non-life-threatening cutaneous herpes simplex virus infections in immunocompromised patients. The prophylactic use of this preparation has not been established. Pr ZOVIRAX ® Product Monograph Page 2 of 32 In the treatment of genital herpes, appropriate examinations should be performed to rule out other sexually transmitted diseases. Therapy should begin as early as possible after the start of an infection. Whereas cutaneous lesions associated with herpes simplex infections are often pathognomonic, TZANCK smears prepared from lesion exudate or scrapings may assist in the diagnosis. Positive cultures for herpes simplex virus offer the only absolute means for confirmation of the diagnosis. These indications are based on … https://pdf.hres.ca/dpd_pm/00059349.PDF PM date: December 22, 2020 Source product: ZOVIRAX; DIN 00569771; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.